In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 36, No. 7_suppl ( 2018-03-01), p. 34-34
Kurzfassung:
34 Background: The number of cancer survivors in Ontario has grown rapidly due to increasing incidence and advances in screening, diagnostic technologies and treatment. However, there is a lack of information to plan, monitor and improve follow-up care. Using the Ontario Cancer Registry (OCR) and health services administrative data, we developed a cohort of cancer survivors from which we could determine demographic characteristics, where follow-up care was received, and concordance with guideline-recommended surveillance testing. Methods: Individuals were included in the cumulative survivor cohort if they had at least one diagnosed incident malignant cancer from 1964 to 2017 in the OCR. Patients were considered survivors upon completion of treatment (surgery, chemotherapy, radiation therapy). Treatment was ascertained from clinical and administrative data using a data-driven approach combined with clinical expert input. In the absence of recurrence data, a treatment-based proxy was developed. Stage IV and complex malignant haematology cancer patients were excluded. We did a cross-sectional analysis of survivors in the cohort in 2016. We produced descriptive statistics and also determined the year of survivorship. For those who were in their first to fifth year of survival, we calculated the proportion who saw a medical or radiation oncologist (MO/RO) in 2016 stratified by year of survivorship. Results: As of December 31, 2016, there were 414,134 cancer survivors in the cohort, roughly 3% of the Ontario population. Ninety-three percent of survivors had a single primary cancer diagnosis, 66% were aged 65 or older, and slightly more were female (55%). Also, 22% had been diagnosed with breast cancer, 22% with prostate, and 12% with colorectal cancer. For those in their first year of survivorship, roughly 50% saw a MO/RO; whereas, for those in their fifth year of survival, 36% had seen a MO and 27% had seen an RO. Conclusions: The development of a cancer survivor cohort has enabled us to produce timely data on a previously unidentified patient population. Linking this cohort with existing administrative data will enable further examination of visit trajectories as well as cancer and non-cancer health outcomes.
Materialart:
Online-Ressource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.2018.36.7_suppl.34
Sprache:
Englisch
Verlag:
American Society of Clinical Oncology (ASCO)
Publikationsdatum:
2018
ZDB Id:
2005181-5
